Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J C Escher

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Journal of Pediatric Gastroenterology and Nutrition|July 31, 2008
Refractory inflammatory bowel disease in childrenM Oliva-Hemker, J C Escher, D Moore, et al.
Alimentary Pharmacology & Therapeutics|April 14, 2006
Pharmacogenetics of thiopurine therapy in paediatric IBD patientsL De Ridder, J M Van Dieren, H J H Van Deventer, et al.
European Journal of Human Genetics : EJHG|October 4, 2024
Biallelic and monoallelic variants in EFEMP1 can cause a severe and distinct subtype of heritable connective tissue disorderM O Mol, T J van Ham, N Bannink, et al.
Mucosal Immunology|December 14, 2018
IL-10 signaling prevents gluten-dependent intraepithelial CD4<sup>+</sup> cytotoxic T lymphocyte infiltration and epithelial damage in the small intestineL M M Costes, D J Lindenbergh-Kortleve, L A van Berkel, et al.
Alimentary Pharmacology & Therapeutics|June 14, 2018
Clinical disease activity is associated with anxiety and depressive symptoms in adolescents and young adults with inflammatory bowel diseaseG van den Brink, L Stapersma, L E Vlug, et al.
Alimentary Pharmacology & Therapeutics|November 19, 2010
The duration of effect of infliximab maintenance treatment in paediatric Crohn's disease is limitedC I De Bie, T Z Hummel, A Kindermann, et al.
Gut|February 17, 2006
European evidence based consensus on the diagnosis and management of Crohn's disease: special situationsR Caprilli, M A Gassull, J C Escher, et al.
Mucosal Immunology|August 17, 2019
IL-10 signaling in dendritic cells controls IL-1β-mediated IFNγ secretion by human CD4<sup>+</sup> T cells: relevance to inflammatory bowel diseaseS Veenbergen, P Li, H C Raatgeep, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 4, 2026
Randomized trial comparing 5-year follow-up of first-line infliximab to conventional therapy in paediatric Crohn's diseaseS A Vuijk, M M E Jongsma, M A Cozijnsen, et al.
Journal of Crohn'S & Colitis|June 10, 2014
Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's diseaseF M Ruemmele, G Veres, K L Kolho, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Journal of Pediatric Gastroenterology and Nutrition|July 31, 2008
Refractory inflammatory bowel disease in childrenM Oliva-Hemker, J C Escher, D Moore, et al.
Alimentary Pharmacology & Therapeutics|April 14, 2006
Pharmacogenetics of thiopurine therapy in paediatric IBD patientsL De Ridder, J M Van Dieren, H J H Van Deventer, et al.
European Journal of Human Genetics : EJHG|October 4, 2024
Biallelic and monoallelic variants in EFEMP1 can cause a severe and distinct subtype of heritable connective tissue disorderM O Mol, T J van Ham, N Bannink, et al.
Mucosal Immunology|December 14, 2018
IL-10 signaling prevents gluten-dependent intraepithelial CD4<sup>+</sup> cytotoxic T lymphocyte infiltration and epithelial damage in the small intestineL M M Costes, D J Lindenbergh-Kortleve, L A van Berkel, et al.
Alimentary Pharmacology & Therapeutics|June 14, 2018
Clinical disease activity is associated with anxiety and depressive symptoms in adolescents and young adults with inflammatory bowel diseaseG van den Brink, L Stapersma, L E Vlug, et al.
Alimentary Pharmacology & Therapeutics|November 19, 2010
The duration of effect of infliximab maintenance treatment in paediatric Crohn's disease is limitedC I De Bie, T Z Hummel, A Kindermann, et al.
Gut|February 17, 2006
European evidence based consensus on the diagnosis and management of Crohn's disease: special situationsR Caprilli, M A Gassull, J C Escher, et al.
Mucosal Immunology|August 17, 2019
IL-10 signaling in dendritic cells controls IL-1β-mediated IFNγ secretion by human CD4<sup>+</sup> T cells: relevance to inflammatory bowel diseaseS Veenbergen, P Li, H C Raatgeep, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 4, 2026
Randomized trial comparing 5-year follow-up of first-line infliximab to conventional therapy in paediatric Crohn's diseaseS A Vuijk, M M E Jongsma, M A Cozijnsen, et al.
Journal of Crohn'S & Colitis|June 10, 2014
Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's diseaseF M Ruemmele, G Veres, K L Kolho, et al.
Pageof 3